{"entity":{"id":"nct06636682","kind":"trial","name":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","aka":[],"tldr":"A phase 2 trial of FK-PC101 in prostate cancer, run by Cellvax Therapeutics Inc, now recruiting.","summary":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer is a phase 2 interventional study registered as NCT06636682 by Cellvax Therapeutics Inc, with 100 participants planned, started 2024-10-14 and due to reach its primary completion in 2027-02-02. Interventions recorded: FK-PC101 and Standard of Care (SOC).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06636682","url":"https://clinicaltrials.gov/study/NCT06636682"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06636682","phase":"2","setting":"A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy","sponsor":"Cellvax Therapeutics Inc","enrolled":100,"outcomes":[]},"route":"/trials/nct06636682/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}